Hospital Pablo Tobón Uribe
Hospital Pablo Tobón Uribe
CL 78B #69 - 240, Cordoba, Medellín, Robledo, Medellín, Antioquia, Colombia
Select an option
I am a doctor
I am a sponsor
Specializations
Our team
Medical staff
Ivan Dario Jaramillo
Gabriel Mosquera
Kelly Johanna Franco
Javier Dario Marquez
Ana Maria Gonzalez
Open studies
Lupus
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus - SELECT-SLE - AbbVieSee more
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus - OPUS-1 - Idorsia Pharmaceuticals Ltd.See more
Multiple myeloma
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) - SUCCESSOR-2 - Bristol-Myers SquibbSee more
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma - EXCALIBER Maintenance - Bristol-Myers SquibbSee more
Non-Hodgkin Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) - waveLINE-003 - Merck Sharp & Dohme LLCSee more
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) - waveLINE-010 - Merck Sharp & Dohme LLCSee more
Myelodysplastic Syndromes
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions - ELEMENT-MDS - Bristol-Myers SquibbSee more
Myeloproliferative syndromes
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment - MYF3001 - Geron CorporationSee more
